More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first ...

Hyderabad: Aurobindo Pharma has announced that Curateq Biologics Private Limited, a wholly owned subsidiary of the Company, ...

What is the difference between prediabetes and diabetes, and which do I have? I am male, 85 years old, 170 pounds, and 6 feet ...

Emraan Hashmi has been diagnosed with dengue. Since monsoon season is coming, know how to protect yourself from getting ...

Tofu is a good meat alternative with protein, vitamins, and minerals. If you’re skeptical about tofu, read on to learn its ...

Researchers from the University of Southampton will join the Breast Walk Ever charity event on 8 June 2025 to support Against Breast Cancer and r ...

Bone is a common site for metastasis of solid cancers, but histological and molecular features of bone metastases are not ...

A study presented at COMy 2025 shows that dual testing for minimal residual disease (MRD) using both bone marrow flow ...

BIOVF shifts to a strategic portfolio emphasizing Haematology, driving strong revenue growth. Key catalysts in 2025.

In the evolving landscape of haematologic cancers, the concept of minimal residual disease, also known as measurable residual ...

BioMarin agreed to shell out approximately $270 million for Inozyme Pharma, a developer whose treatments target the PPi-adenosine pathway, a key regulator of bone health and blood vessel function.